Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Phenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.65 |
| ▸ | ALPI | P09923 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | XIAP | P98170 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.49 |
| ▸ | CPA3 | P15088 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 3/20 | 0.46 |
| ▸ | NOS1 | P29475 | 3/20 | 0.46 |
| ▸ | NOS2 | P35228 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | TPH1 | P17752 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL10428542 | 1.00 | SLC7A5 (0.65) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL21905169 | 1.00 | SLC7A5 (0.65) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL10428543 | 1.00 | SLC7A5 (0.65) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL28638756 | 0.94 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL3630630 | 0.94 | SLC7A5 (0.73) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL1675409 | 0.94 | SLC7A5 (0.73) | SLC7A5ALPIPKMPTGS1XIAP | |
| Tyrosine SCHEMBL27245949 | 0.93 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL23152420 | 0.91 | SLC7A5 (0.69) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL20994022 | 0.91 | SLC7A5 (0.69) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL21410077 | 0.91 | SLC7A5 (0.69) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 824 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200138737-A1 | COMPOSITION COMPRISING CANNABINOIDS FOR RELIEF OF PAIN | JGB COLLATERAL LLC | 2020-05-07 | — | — | US | claimed |
| US-9850294-B2 | IL-17R-ECD mutants and methods of using same | THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV, LTD. (IL) | 2017-12-26 | — | — | US | claimed |
| US-20160376343-A1 | NOVEL IL-17R-ECD MUTANTS | THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV, LTD. | 2016-12-29 | — | — | US | claimed |
| US-9416168-B2 | IL-17R-ECD mutants and methods of using same | The National Institute for Biotechnology in the Negev, Ltd (IL) | 2016-08-16 | — | — | US | claimed |
| EP-2844733-A1 | IN VITRO MODEL FOR PATHOLOGICAL OR PHYSIOLOGIC CONDITIONS | Hemoshear, LLC (US) | 2015-03-11 | — | — | EP | claimed |
| EP-2734541-A2 | NOVEL IL-17R-ECD MUTANTS | The National Institute for Biotechnology in the Negev, Ltd. (IL) | 2014-05-28 | — | — | EP | claimed |
| WO-2013158939-A1 | IN VITRO MODEL FOR PATHOLOGICAL OR PHYSIOLOGIC CONDITIONS | HEMOSHEAR, LLC (US) | 2013-10-24 | — | — | WO | claimed |
| WO-2013011368-A2 | NOVEL IL-17R-ECD MUTANTS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2013-01-24 | — | — | WO | claimed |
| WO-2013012498-A1 | ELECTRIC CELL- SUBSTRATE IMPEDANCE SENSING (ECIS) OF BIOLOGICAL SAMPLES IN SHEAR STRESS FLOW | HEMOSHEAR, LLC (US) | 2013-01-24 | — | — | WO | claimed |
| CN-102791273-A | Small pyrimidine derivatives and methods of use thereof | PROTEOLOGICS LTD | 2012-11-21 | — | — | CN | claimed |
| EP-2521548-A2 | QUINAZOLIN-4(3A)-ONE DERIVATIVES AND METHODS OF USE THEREOF | Proteologics, Ltd (IL) | 2012-11-14 | — | — | EP | claimed |
| EP-2509601-A1 | SMALL PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | Proteologics, Ltd (IL) | 2012-10-17 | — | — | EP | claimed |
| WO-2011064661-A1 | SMALL PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | PROTEOLOGICS, LTD. (IL) | 2011-06-03 | — | — | WO | claimed |
| WO-2011064657-A2 | QUINAZOLIN-4(3A)-ONE DERIVATIVES AND METHODS OF USE THEREOF | PROTEOLOGICS, LTD. (IL) | 2011-06-03 | — | — | WO | claimed |
| US-20110130374-A1 | Small Pyrimidine Derivatives and Methods of Use Thereof | BIOSEARCH(2007) LTD. (IL) | 2011-06-02 | — | — | US | claimed |
| US-20110129463-A1 | Quinazolin-4(3A)-One Derivatives and Methods of Use Thereof | PROTEOLOGICS, LTD. (IL) | 2011-06-02 | — | — | US | claimed |
| CN-111936487-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-07-09 | — | — | CN | disclosed |
| US-12030946-B2 | Therapeutic and diagnostic methods for cancer | HOFFMANN-LA ROCHE INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20110130374-A1 | Small Pyrimidine Derivatives and Methods of Use Thereof | BIOSEARCH(2007) LTD. (IL) | 2011-06-02 | — | — | US | disclosed |
| US-20110129463-A1 | Quinazolin-4(3A)-One Derivatives and Methods of Use Thereof | PROTEOLOGICS, LTD. (IL) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110129463-A1 | Quinazolin-4(3A)-One Derivatives and Methods of Use Thereof | USP3, CUL3, UBQLN1 | SLC7A5 4036/4885ALPI 1670/4885PKM 2955/4885 |
| US-20110130374-A1 | Small Pyrimidine Derivatives and Methods of Use Thereof | TYMS, UPP1, DPYD | SLC7A5 1588/4885ALPI 3255/4885PKM 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.